Regarding the Situation with…Social Media in General

Regarding the Situation with…Twitter, Bluesky, Social Media

We at #NephJC pride ourselves on bringing you the best in nephrology publications and innovations without commercial bias. As we’ve stated during many a donation drive, we are beholden to none but our followers and readers.

Having said that, we’ve noticed a trend since the death of Twitter (yes, it will always be Twitter to the real FOAMed illuminati). The diaspora of NephTwitter were scattered throughout the nephro-universe of social media, never quite finding a new home. Perhaps the downfall of the Nephrologians can be a plot line for the next Mandalorian season?? Many left the social media space altogether because of the division, politicization and plain BS of some of the algorithms (I for one don’t need to see EVERYTHING Elon posts). However, we still believe there is a need for our unique style of nephrology education. Jon Stewart- yes, the comedian- recently likened social media to smoking: an addictive, attention seeking habit that is generally recognized as not healthy for most people and that is likely to be regulated for teen and self-regulate by adults. He believed the antidote was more long-form, nuanced edu-tainment. So, it light of the changing landscape, we are going to focus more on our blogs, VAs, and podcasts and less on live discussions on Bluesky.

NephJC is nothing if not nimble, and we have never been afraid of change.

So, given the low attendance at live chats (no judgement) we’re changing to a summary thread (a new 10 posts) with provocative questions to answer, at your leisure. We hope this keeps the discussions going without the need to be on social media for prolonged periods or at a specific hour and day. These threads will be posted at the familiar 9pm EST every other Tuesday. This shorter form will also allow us to post on multiple sites, and hopefully we will be easily accessible to you where you chat with other nephrophiles. Feel free to reply, chat, tag people in conversations whenever and wherever you see a #NephJC post. The team will be around, but we won’t be actively ‘moderating’ a one hour chat.

Sincerely,

NephJC Leadership


PS: As always we love to hear from our audience. If you have suggestions, or a better way to reach more people, we are all ears. Heck, if we hear enough complaints we might even bring back the chats!😉

Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia

Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia

This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?

Hiponatremia: El Resumen Visual

La hiponatremia es uno de los trastornos electrolíticos más frecuentes en pacientes hospitalizados y se asocia de manera consistente con peores desenlaces. Su corrección mejora los valores, pero ¿realmente mejora los desenlaces clínicos ?

Revisa el resumen visual por Brian Rifkin y el nuevo formato de #NephJC

Announcing the NephJC Editorial Internship

Are you a curious, motivated nephrology fellow or early‑career faculty member with a passion for science communication? NephJC is inviting a small group of talented individuals to join our Editorial Internship Program and become part of the team that shapes how nephrology is discussed, illustrated, and shared online.

As an intern, you’ll help craft the bimonthly NephJC Journal Club, one of the most vibrant hubs for post‑publication peer review in nephrology, while developing your skills as an editor, writer, illustrator, or podcaster. We’re also planning to expand our Instagram presence this year, so creative voices with an eye for visual storytelling will have new opportunities to shine.

What this internship offers

  • Collaboration with an experienced, dynamic production team

  • Engagement with cutting‑edge nephrology research

  • Increased professional visibility within the global nephrology community

Take your passion for kidneys, curiosity, and community to the next level- join the NephJC Editorial Internship Program and help us keep the nephrology spirit alive across platforms, including a more active IG presence.

REACT: El Resumen Visual

REACT aterriza a #NephJC

Esta vez analizamos rilparencel, una terapia celular renal autóloga inyectada directamente en la corteza renal para enlentecer la perdida de la función renal en nefropatía diabética y ERC avanzada.

¿Estamos ante una nueva era en la nefrología?

Revisa el resumen visual por Natalia Nombera y únete a la discusión en #NephJC.

REACT: The Visual Abstract

REACT has landed to NephJC.

This time we explore rilparencel, an autologous kidney cell therapy injected directly into the renal cortex to slow kidney function decline in DKD and advanced CKD.

Is this the future of regenerative nephrology?

Take a look at the Visual Abstract Natalia Nombera and join the conversation on #NephJC.

2026 #NephJCKidneys vote begins

After an extended nomination period, it is time to vote for your favorites. Like in the previous years, you will need to be a subscriber to the newsletter to be eligible to vote. By voting you let our content creators know how much they are contributing the the FOAMed goals of NephJC.

Just one week to vote!

The link to vote will be available in the newsletter.

Here is the final ballot:

Article of the Year

Engaged Scientist of the Year

Nathan Hellman Social Media Project of the Year

Most Valuable Player

Milagros Flores @dramiliflores.bsky.social

Brian Rifkin @brianrifkin.bsky.social

Akshaya Jaychandran @nephromommy-akshu.bsky.social

Visual Abstract of the Year

ISN-GKHA interactive map: From data to dialogue by Denisse Arellano

Akshaya Jaychandran ACHIEVE trial 

Husam Alzayer: incremental dialysis

Krithika Mohan: herb nephropathy

NephJC Social Justice Award

WHO kidney resolution and UN political declaration

World KIdney Day- Kidney health for all

KDIGO 2026 Anemia in CKD: The Visual Abstract

Anemia remains a central challenge in chronic kidney disease, influencing quality of life, cardiovascular risk, and clinical outcomes. The updated KDIGO 2026 guideline provides practical recommendations on iron management, ESAs, HIF-PHIs, and transfusion strategies, emphasizing individualized care and risk–benefit assessment.

Take a quick look at the VA by Michelle Fravel summarizing the key concepts and clinical take-home message

KDIGO 2026 Anemia en la ERC: El Resumen Visual

La anemia continúa siendo un reto clave en la enfermedad renal crónica, con impacto directo en la calidad de vida, el riesgo cardiovascular y los desenlaces clínicos. La actualización KDIGO 2026 ofrece recomendaciones prácticas sobre el manejo del hierro, el uso de AEEs, PHI-HIFs y estrategias de transfusión, con énfasis en una toma de decisiones individualizada basada en riesgo-beneficio.

Revisa el resumen visual realizado por Michelle Fravel , donde resume los mensajes clave y las principales perlas clínicas de la guía 2026.

INFINITI: The Visual Abstract

SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.

Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar